3-iodobenzylguanidine has been researched along with valsartan in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Daimon, M; Fujita, M; Komuro, I; Kuwabara, Y; Mizuma, H; Nakayama, K; Narumi, H; Shindo, S | 1 |
| Ahn, Y; Bom, HS; Cho, JG; Cho, JY; Chong, A; Hong, YJ; Jang, SY; Jeong, HC; Jeong, IS; Jeong, MH; Kang, JC; Kim, HK; Kim, J; Kim, JH; Kim, JM; Kim, KH; Kim, MS; Kim, SS; Lee, KH; Lim, KS; Oh, SG; Park, DS; Park, HW; Park, JC; Park, KH; Ryu, SH; Sim, DS; Song, HC; Yoon, HJ; Yoon, NS | 1 |
3 trial(s) available for 3-iodobenzylguanidine and valsartan
| Article | Year |
|---|---|
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Treatment Outcome; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart; Heart Failure; Humans; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Observer Variation; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2006 |
Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.
Topics: 3-Iodobenzylguanidine; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Statistical; Endpoint Determination; Female; Follow-Up Studies; Humans; Hypertension; Informed Consent; Male; Middle Aged; Patient Selection; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Research Design; Risk Factors; Sample Size; Tetrazoles; Ultrasonography; Valine; Valsartan | 2008 |
1 other study(ies) available for 3-iodobenzylguanidine and valsartan
| Article | Year |
|---|---|
Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.
Topics: 3-Iodobenzylguanidine; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Fluorodeoxyglucose F18; Perindopril; Positron-Emission Tomography; Pyrimidines; Random Allocation; Swine; Tetrazoles; Tomography, Emission-Computed, Single-Photon; Valsartan; Ventricular Function, Left | 2015 |